Home
News
Create
Screeners
Insights
Godavari Drugs
115.
10
-3.41
(-2.88%)
Market Cap
₹116.55 Cr
PE Ratio
27.43
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.88%
1M
+33.84%
6M
+35.30%
1Y
+23.66%
5Y
+81.55%
View Company Insights
Latest news about Godavari Drugs
Godavari Drugs Limited Submits SEBI Compliance Certificate for Q4FY26
Apr 08, 2026
Godavari Drugs Limited submitted its SEBI Regulation 74(5) compliance certificate for Q4FY26 to BSE Limited on April 8, 2026. The certificate, issued by registrar CIL Securities Limited, confirms proper handling of dematerialization processes during the quarter ended March 31, 2026, including verification of securities, cancellation of certificates, and timely substitution of depository names in the Register of Members.
Godavari Drugs: Prashant Shrimal Files SEBI Disclosure for Share Acquisition
Mar 23, 2026
Godavari Drugs Limited Shareholders Approve Preferential Equity Share and Convertible Warrant Issuance at EGM
Feb 12, 2026
Godavari Drugs Reports Q3FY26 Results, Approves ₹5.50 Crore Working Capital Loan
Feb 11, 2026
Godavari Drugs Board Approves Preferential Issue of Convertible Warrants and Equity Shares Worth ₹44.12 Crores
Jan 15, 2026
More news about Godavari Drugs
08
Jan 26
Godavari Drugs Limited Issues Clarification on Share Price Movement to BSE
Godavari Drugs Limited submitted a clarification to BSE on January 8, 2026, regarding significant share price movement, confirming no unpublished price sensitive information exists. The company attributed the price volatility to market-driven demand-supply factors and reaffirmed its commitment to regulatory compliance under SEBI regulations.
Godavari Drugs
115.
10
-
3.
41
(-
2.
88
%)
1 Year Returns:
+23.66%
Industry Peers
Sun Pharmaceutical
1,620.40
(-
3.
55
%)
Divis Laboratories
6,361.50
(-
0.
27
%)
Torrent Pharmaceuticals
4,117.20
(-
0.
72
%)
Dr Reddys Laboratories
1,317.10
(-
1.
04
%)
Lupin
2,296.10
(-
1.
93
%)
Cipla
1,295.00
(-
0.
83
%)
Mankind Pharma
2,267.40
(-
1.
11
%)
Zydus Life Science
927.40
(-
2.
00
%)
Aurobindo Pharma
1,413.80
(-
1.
50
%)
Glenmark Pharmaceuticals
2,299.50
(-
1.
52
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO